Kate Kelley
Health Sciences Professor of Clinical Medicine · University of California (San Francisco) School of Medicine
Credentials: · · ·
History
1998–2002- 1993–1997
Harvard College
Research
Review · Nature Reviews Disease Primers · 2021 · 5,588 citations
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Review · Journal of Hepatology · 2022 · 3,643 citations
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
New England Journal of Medicine · 2018 · Last of 22 authors · 1,916 citations
- GA
39 papers
38 papers
22 papers
21 papers
- AZ
20 papers
20 papers
18 papers · 1 as a resident
18 papers
Grants
- 2017–2018
Tumor Molecular Profiling and Response to Immunotherapy in Advanced Biliary Cancers
National Cancer Institute · R03
Contact PI · $158.5K · University of California, San Francisco
Clinical trials
- 2018–2023
Principal investigator · Completed · Phase 2
Robin Kate Kelley
- 2009–2013
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Principal investigator · Completed · Phase 1
University of California, San Francisco